Notably, fosgonimetons Phase 2/3 LIFT-AD trial in mild-to-moderate Alzheimers disease missed its primary endpoint in topline results released in 2023
Consequently, the authors of the AJMC study emphasized the importance of guiding patients toward the safe use of compounded GLP-1s
Practitioners who treat chronic illnesses often have patients who tell them, I was healthy until I moved into this building or I feel better when I leave for work or a vacation, but worse when I come home. If any of this sounds familiar, you should check your house and other buildings you spend significant time in for water damage, leaks, humidity, and mold growth
Youre after hydration, glow, or just want to keep things simple
hold a published patent (WO/2023/180570) that covers the in vitro method for identifying anti-senescence compounds based on detecting the binding of said compound in the presence of at least one phosphorylated amino acid in the transcription activation domain (TAD) domain of mammalian protein p53
It might not just be one of those days